Johnson & Johnson Articles
Neurochem's loss falls 16% in fiscal 3rd qtr
19 November 2007
Syntaxin raises L16M in series B round
12 November 2007
Mylan's earnings soar 94% in fiscal 2nd-qtr
12 November 2007
US insurer updates anemia drug policies
29 October 2007
Galapagos NV and Janssen Pharmaceutica enter RA drug R&D accord
29 October 2007
Stada's Silapo gets CHMP thumbs up
29 October 2007
FDA clears Ortho-McNeil's Doribax
22 October 2007
Stores clear pediatric cough and cold remedies from shelves
22 October 2007
Addendum: Janssen/J&J's Invega
22 October 2007
Bayer/J&J's Xarelto will drive anticoagulant market
22 October 2007
Charges hit J&J's third qtr; forecast raised
22 October 2007
Drugmakers withdraw child cold remedies
22 October 2007
Invega signficantly cuts schizophrenia vs Seroquel
22 October 2007
J&J's NHS money-back guarantee warning
22 October 2007
Strong Ph III data for J&J/Basilea's ceftobiprole
15 October 2007
Ustekinumab helps patients achieve PASI-75
15 October 2007
J&J's Topamax may help alcoholics quit
15 October 2007
Eli Lilly CEO Taurel calls for reform of US drug safety system
15 October 2007
Isis Pharma cuts 2007 net operating loss prediction
15 October 2007
Opposite ratings for Swiss bio firms Arpida and Basilea
8 October 2007
Isis pays $120M for Symphony GenIsis
8 October 2007
J&J's doripenem fares well vs NP and VAP
1 October 2007
90% cure rate for MRSA cSSSI with J&J's ceftobiprole
1 October 2007
Asche Chiesi and Janssen-Cilag to co-market asthma drugs
27 September 2007
Janssen-Cilag announces job cuts
24 September 2007
US pharmacists oppose new Medicaid Rx rule
24 September 2007
Janssen and AstraZeneca drugs now lead antipsychotics
24 September 2007
FDA clears new indication for Ortho-McNeil's Levaquin
24 September 2007
"Wisdom of crowds" will transform doctor-patient relationships
17 September 2007
FDA panel votes against restricting ESA dose
17 September 2007
NICE complies with UK court's AD ruling
17 September 2007
Cypher fares well vs bare metal stents
10 September 2007
EU to investigate UK's drug "postcode lottery"
10 September 2007
US oncology docs want CMS anemia drug review
10 September 2007
Japan stock market week to August 27, 2007
3 September 2007
FDA clears Risperdal for two new indications
3 September 2007
NICE announce AD drug clarification "within 28 days"
20 August 2007
ImClone recruits John Johnson as CEO
20 August 2007
UK cancer drug access under fire again
20 August 2007
Competition in the venous thromboembolism market
20 August 2007
Domestic vs JV drug prices in China differ
20 August 2007
J&J sues American Red Cross over signature emblem
13 August 2007
Alkermes sees fiscal 1st-qtr net income of $8.7M
13 August 2007
Actavis launches Griseofulvin in USA
6 August 2007
Tibotec files TMC125 MAA with EMEA
6 August 2007
J&J cost restructuring will see 4,800 job cuts
6 August 2007
Boeh Ing's 1st half 2007 sales up 2.1%
6 August 2007
Wyeth's 2nd-qtr net income climbs 12.5%
30 July 2007
Par and Ortho-McNeil resolve Ultracet patent dispute
30 July 2007
J&J submits MAA for doripenem to EMEA
30 July 2007
J&J to make $10 billion share buyback
26 July 2007
J&J's 2nd-qtr 2007 net income jumps 9.2%
23 July 2007
Alzheimer's case concludes in UK High Court
9 July 2007
Stock Commentary - New York week to July 2, 2007
9 July 2007
J&J's Invega approved in UK for schizophrenia
9 July 2007
Strong Ph I/II data for Keryx' perifosine
9 July 2007
Velcade produces 54% CR rate in MM
9 July 2007
UK court puts NICE AD drug limits on trial
2 July 2007
FDA "approvable" letter for J&J's Risperdal sNDAs
25 June 2007
Ceftobiprole MAA submitted to EMEA
25 June 2007
Bayer to showcase health care business to analysts
18 June 2007
Neurochem 1st-qtr loss soars 44% on R&D costs
11 June 2007
J&J submits NDA to FDA for ceftobiprole
28 May 2007
Combined Velcade plus Doxil gets FDA OK for MM
28 May 2007
CMS moves quickly on ESA coverage limits
21 May 2007
Japan stock market week to May 14, 2007
21 May 2007
Japanese regulator gives nod to three new drugs
21 May 2007
Australian R&D tax breaks announced
14 May 2007
Peptech to buy EvoGenix for $129M
14 May 2007
Neuromed licenses ALZA's OROS painkiller
7 May 2007
Invega gets nod from CHMP
7 May 2007
J&J's 1st-qtr profits slip 22% on Conor buy
23 April 2007
FDA approves new Risperdal Consta dose
23 April 2007
J&J adopts a "post-DTC" marketing approach
23 April 2007
J&J's Ditropan to get stronger warnings
16 April 2007
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
